X

ASH 2021: Updates in MF

ASH 2021: Updates in MF

AVID200 Improves Platelet Counts Among Patients With Advanced Myelofibrosis

AVID200 led to significant reduction in serum transforming growth factor beta levels and improved platelet counts among patients with advanced myelofibrosis, according to study results presented at

Healio
12/13/2021
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Pembrolizumab was associated with changes in the immune milieu that could potentially support antitumor immunity in patients with advanced MPNs.

Blood Advances
12/03/2021
Bleeding Risks in Patients With MPNs Increased With Anticoagulant Use, Antiplatelet Therapy

Study findings suggest that patients with BCR–ABL-negative myeloproliferative neoplasms are at increased risk of bleeding events while on antiplatelet or anticoagulation therapies.

Hematology Advisor
12/02/2021

Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition

NEWTON, Mass., Nov. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with myelofibrosis (MF) previously treated with JAK inhibition has been selected for an oral presentation at the upcoming ASH 2021 Annual Meeting and Exposition in Atlanta, GA on December 11-14, 2021.

12/04/2021
More Than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), held December 11–14, 2021 in Atlanta, Georgia and virtually.

11/04/2021
Phase 3 and 2 Trials Highlight Feasibility of Pacritinib in MF

Results on the compassionate use of pacritinib after the phase 3 PERSIST-1, PERSIST-2, and phase 2 PAC203 trials were presented at the 2021 ASH Annual Meeting to...

Oncology Learning Network
12/02/2021
JAK and P13K Inhibitors Found Beneficial for Patients with MF, Low Platelet Counts

An ongoing subgroup analysis from a phase 2 trial of parsaclisib in patients with myelofibrosis and low platelet counts were presented at the 2021 Annual ASH Meeting.

Oncology Learning Network
12/01/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(80,199,199)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb(11, 160, 224)
#cc529a
#c59445
rgb(245, 111, 66)
#c8cc0c
#bf6be3
rgb (245, 152, 2)
rgb(164, 116, 173)
rgb(219, 105, 96)
#e8085a
rgb(66, 135, 245)
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(125, 127, 130)
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(107, 129, 201)
rgb (214, 104, 96)
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
rgb(214, 139, 202)
#c20fce
rgb(80,199,199)
#d95d39
#eb5834